Computational modeling of the immune response in multiple sclerosis using epimod framework
暂无分享,去创建一个
Marco Beccuti | Simone Pernice | Marzio Pennisi | Laura Follia | Francesca Cordero | Alessandro Maglione | Francesco Pappalardo | Francesco Novelli | Marinella Clerico | Simona Rolla | F. Pappalardo | M. Pennisi | F. Cordero | M. Beccuti | F. Novelli | M. Clerico | S. Rolla | A. Maglione | Laura Follia | S. Pernice
[1] B. Trapp,et al. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis , 2011, Progress in Neurobiology.
[2] Syed Ijlal Ahmed,et al. Risk of Multiple Sclerosis in Epstein–Barr Virus Infection , 2019, Cureus.
[3] Matt Shirley,et al. Daclizumab: A Review in Relapsing Multiple Sclerosis , 2017, Drugs.
[4] Marco Beccuti,et al. 30 Years of GreatSPN , 2016 .
[5] J. Libbey,et al. Molecular Mimicry in Multiple Sclerosis , 2007, International Review of Neurobiology.
[6] Alessandro Maglione,et al. The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis , 2020, Cells.
[7] W. L. Benedict,et al. Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.
[8] D. Sojka,et al. Mechanisms of regulatory T‐cell suppression – a diverse arsenal for a moving target , 2008, Immunology.
[9] Milanesi Luciano,et al. Integrating Petri Nets and Flux Balance Methods in Computational Biology Models : a Methodological and Computational Practice , 2019 .
[10] Francesco Novelli,et al. Th22 cells are expanded in multiple sclerosis and are resistant to IFN‐β , 2014, Journal of leukocyte biology.
[11] Ferdinando Chiacchio,et al. Relapsing-remitting multiple scleroris and the role of vitamin D: an agent based model , 2014, BCB.
[12] Abdul Mateen Rajput,et al. Agent based modeling of Treg-Teff cross regulation in relapsing-remitting multiple sclerosis , 2013, BMC Bioinformatics.
[13] Daniela Paolotti,et al. A computational framework for modeling and studying pertussis epidemiology and vaccination , 2020, BMC Bioinformatics.
[14] Jefferson Becker,et al. Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications , 2016, Mediators of inflammation.
[15] Heinz Wiendl,et al. The role of regulatory T cells in multiple sclerosis , 2008, Nature Clinical Practice Neurology.
[16] Till Sprenger,et al. Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study , 2020, Journal of Neurology.
[17] F. Quintana,et al. [Immunopathology of multiple sclerosis]. , 2014, Medicina.
[18] A. Steelman,et al. Infection as an Environmental Trigger of Multiple Sclerosis Disease Exacerbation , 2015, Front. Immunol..
[19] Hong Li,et al. Efficient formulation of the stochastic simulation algorithm for chemically reacting systems. , 2004, The Journal of chemical physics.
[20] Francesco Pappalardo,et al. Agent based modeling of the effects of potential treatments over the blood-brain barrier in multiple sclerosis. , 2015, Journal of immunological methods.
[21] Michael A. Gibson,et al. Efficient Exact Stochastic Simulation of Chemical Systems with Many Species and Many Channels , 2000 .
[22] D. Gillespie. Exact Stochastic Simulation of Coupled Chemical Reactions , 1977 .
[23] T. Mcclanahan,et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation , 2005, The Journal of experimental medicine.
[24] Marco Beccuti,et al. A computational approach based on the colored Petri net formalism for studying multiple sclerosis , 2019, BMC Bioinformatics.
[25] Jos H. Beijnen,et al. Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies , 2010, Clinical pharmacokinetics.
[26] E. Andrès,et al. CD56bright natural killer (NK) cells: an important NK cell subset , 2009, Immunology.
[27] Beccuti Marco,et al. Estimating Daclizumab effects in Multiple Sclerosis using Stochastic Symmetric Nets , 2018, 2018 IEEE International Conference on Bioinformatics and Biomedicine (BIBM).
[28] D. Gillespie. Approximate accelerated stochastic simulation of chemically reacting systems , 2001 .
[29] Marco Ajmone Marsan,et al. Modelling with Generalized Stochastic Petri Nets , 1995, PERV.
[30] Nathalie Arbour,et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation , 2007, Nature Medicine.
[31] Behzad Baradaran,et al. The role of B cells in the immunopathogenesis of multiple sclerosis , 2020, Immunology.
[32] Marco Beccuti,et al. Integrating Petri Nets and Flux Balance Methods in Computational Biology Models: a Methodological and Computational Practice , 2020, Fundam. Informaticae.
[33] Laura Conti,et al. T‐helper 17 cells expand in multiple sclerosis and are inhibited by interferon‐β , 2009, Annals of neurology.
[34] F Zipp,et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis , 2018, European journal of neurology.
[35] Joaquín Goñi,et al. Modeling the effector - regulatory T cell cross-regulation reveals the intrinsic character of relapses in Multiple Sclerosis , 2011, BMC Systems Biology.
[36] Gavin Giovannoni,et al. Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies , 2019, Trends in Molecular Medicine.
[37] Ryozo Ohno,et al. [Cerebrospinal fluid in multiple sclerosis]. , 2003, Nihon rinsho. Japanese journal of clinical medicine.
[38] Antonio Uccelli,et al. CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis , 2020, Journal of clinical medicine.
[39] Jia Newcombe,et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. , 2008, The American journal of pathology.